• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sonder Capital Appoints Kate Garrett as Managing Partner to Lead Next Generation of Growth

    4/2/24 8:00:00 AM ET
    $ISRG
    $PRCT
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ISRG alert in real time by email

    Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II

    Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund.

    With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created positions of Co-chairs to help guide and support future growth. This strategic move comes as Sonder continues to accelerate innovation, foster innovative leadership, and invest in the next generation of transformative healthcare technologies.

    A respected and well-known leader in the healthcare innovation community, Garrett serves on the board of Sonder portfolio companies Spirair, BRIUS Technologies, Ziteo, and Neptune Medical. She brings nearly two decades of experience as a successful inventor, founder, and operator across a wide spectrum of companies from early-stage startups to multinational organizations. Among her many achievements, Garrett co-founded and led Ciel Medical in the invention, development and commercialization of critical care products for ventilated patients. The company was acquired by Vyaire Medical in 2017. She also serves as Assistant Director of the Stanford Biodesign Innovation Fellowship, where she guides emerging inventors and entrepreneurs in the discovery and development of breakthrough technologies that solve significant unmet healthcare needs.

    "I am honored to have the opportunity to lead our partnership into our next phase of development," said Garrett. "With unsustainable costs and an aging patient population, the fundamental need for better healthcare solutions is as great as ever. These are the types of challenges Sonder is working to address."

    "Kate is the ideal leader for our next generation of growth and innovation," said Watkins. "She is an extraordinary, empathetic team builder who is respected by investors and entrepreneurs alike. Her passion for scaling technologies and developing leaders is critical to our portfolio and firm's success," he said.

    "As we close our second fund, it's crucial for us to have a leader who can collaborate with our partners to build a dynamic infrastructure that will further support and accelerate our growth," said Moll. "Kate has a unique blend of capabilities with her success as an inventor, founder, and operator, and her prominence as a leader and mentor in the healthcare innovation community. Her skills and vision will play a key role in taking us through our next phase of growth," he said.

    About Sonder Capital

    Sonder's team of veteran investors, innovators, founder-operators, and company builders is known not only for their individual achievements, but also for their collective success in creating, funding, and leading private and public companies that have transformed healthcare for millions of patients globally — including Intuitive Surgical (NASDAQ:ISRG), Shockwave Medical (NASDAQ:SWAV), Procept Biorobotics (NASDAQ:PRCT), Auris Health, and Reflexion Medical, among others. Sonder's extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare technologies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, M.D.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240401500277/en/

    Get the next $ISRG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISRG
    $PRCT
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Intuitive Surgical Inc.
    $ISRG
    1/27/2026$660.00Buy
    TD Cowen
    PROCEPT BioRobotics Corporation
    $PRCT
    12/12/2025$62.00Buy
    UBS
    Intuitive Surgical Inc.
    $ISRG
    12/11/2025$635.00Buy → Neutral
    Citigroup
    PROCEPT BioRobotics Corporation
    $PRCT
    12/8/2025$38.00Buy → Neutral
    BofA Securities
    PROCEPT BioRobotics Corporation
    $PRCT
    9/2/2025$60.00Perform → Outperform
    Oppenheimer
    Intuitive Surgical Inc.
    $ISRG
    7/23/2025Buy → Hold
    Erste Group
    PROCEPT BioRobotics Corporation
    $PRCT
    7/9/2025$70.00Overweight
    Stephens
    PROCEPT BioRobotics Corporation
    $PRCT
    7/7/2025Perform
    Oppenheimer
    More analyst ratings

    $ISRG
    $PRCT
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Leonard Keith R disposed of 369 shares, decreasing direct ownership by 50% to 370 units (SEC Form 4)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    1/30/26 9:45:03 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    SEC Form 4 filed by SVP & Chief Mfg and Supply Cha Brosius Mark

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    1/30/26 9:28:38 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    SEC Form 4 filed by EVP & Chief Legal and Complian Loeb Gary

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    1/30/26 9:24:32 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February 24, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it will host an in-person investor day event on Wednesday, February 25, 2026, at the NASDAQ Headquarters in New York City beginning at 8:00am Eastern Time. Guests are encouraged to register in advance by clic

    1/26/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Da Vinci 5 Cleared for Cardiac Procedures

    SUNNYVALE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the da Vinci 5 system for certain cardiac procedures, including mitral valve repair and IMA (internal mammary artery) mobilization for cardiac revascularization.         Cardiovascular disease remains the leading cause of death worldwide, claiming nearly 18 million lives each year.i More than two million patients worldwide undergo open heart surgery annuallyii, with most procedures requiring a sternotomy, an approach that involves splitting

    1/26/26 9:15:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    20 Million Patients Benefit from da Vinci Surgery Globally

    SUNNYVALE, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced that more than 20 million patients worldwide have been operated on by surgeons using da Vinci surgical systems. The milestone was reached as of the end of 2025, with more than 3.1 million da Vinci procedures performed last year alone. This achievement reflects the continued adoption of, and expanded patient access to, Intuitive's minimally invasive technology. "This achievement is a direct result of the dedication of surgeons and care teams around the globe to provide the best possible care for their pat

    1/23/26 9:15:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Intuitive Surgical with a new price target

    TD Cowen initiated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $660.00

    1/27/26 8:46:58 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    UBS initiated coverage on PROCEPT BioRobotics with a new price target

    UBS initiated coverage of PROCEPT BioRobotics with a rating of Buy and set a new price target of $62.00

    12/12/25 8:54:55 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Intuitive Surgical downgraded by Citigroup with a new price target

    Citigroup downgraded Intuitive Surgical from Buy to Neutral and set a new price target of $635.00

    12/11/25 8:53:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SWAV
    SEC Filings

    View All

    SEC Form 10-K filed by Intuitive Surgical Inc.

    10-K - INTUITIVE SURGICAL INC (0001035267) (Filer)

    2/3/26 4:59:59 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    Intuitive Surgical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)

    1/22/26 4:05:12 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    Intuitive Surgical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)

    1/14/26 8:58:49 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Intel Appoints Dr. Craig H. Barratt to Board of Directors

    Intel Corporation (NASDAQ:INTC) today announced that Craig H. Barratt, Ph.D., 63, has been appointed to its board of directors, effective immediately. Dr. Barratt will serve as an independent director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110908011/en/Dr. Craig H. Barratt joins Intel's board as an independent director. "Craig is a highly accomplished technology leader with a proven ability to innovate, scale, and transform businesses," said Lip-Bu Tan, Intel CEO. "He is a seasoned semiconductor executive with experience at multiple leading-edge technology companies, which will be invaluable as we continue to execute

    11/10/25 6:21:00 PM ET
    $ALAB
    $INTC
    $ISRG
    Semiconductors
    Technology
    Industrial Specialties
    Health Care

    30 years of Innovation and Impact: Dan Larson's Inspiring Story

    SUNNYVALE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- When Seattle resident Dan Larson was diagnosed with lung cancer in 2023, his only exposure to robotic technology was through his work as a quality engineer at Boeing. He could never have imagined that robotic technology made by Intuitive, the pioneer of robotic-assisted surgery, would one day play a pivotal role in his health care. Having experienced the loss of his father to lung cancer, Dan was determined to overcome his own diagnosis and enjoy his retirement with his family. Under the care of clinicians at MultiCare Tacoma General Hospital in Washington, Dan underwent two robotic lung biopsies with the Ion Endoluminal System, Intuit

    5/27/25 9:15:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Financials

    Live finance-specific insights

    View All

    PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February 24, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it will host an in-person investor day event on Wednesday, February 25, 2026, at the NASDAQ Headquarters in New York City beginning at 8:00am Eastern Time. Guests are encouraged to register in advance by clic

    1/26/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Intuitive Announces Fourth Quarter Earnings

    SUNNYVALE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2025. Q4 Highlights Worldwide procedures (da Vinci and Ion combined) grew approximately 18% compared with the fourth quarter of 2024. Da Vinci procedures grew approximately 17% and Ion procedures grew approximately 44%.The Company placed 532 da Vinci surgical systems, compared with 493 in the fourth quarter of 2024. The fourth quarter 2025 da Vinci surgical system placements included 303 da Vinci 5 systems, compared with 174 i

    1/22/26 4:05:00 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    Intuitive Announces Preliminary Fourth Quarter and Full Year 2025 Results

    SUNNYVALE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced certain unaudited preliminary fourth quarter and full year 2025 financial results ahead of its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Financial and Operational Highlights Fourth quarter 2025 worldwide procedures (da Vinci and Ion combined) grew approximately 18% compared with the fourth quarter of 2024. Da Vinci procedures grew approximately 17% and Ion procedures grew approximately 44%. Average da Vinci system utilization increased 4%

    1/14/26 9:05:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/12/24 5:01:10 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/4/24 1:31:19 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care